Cindy S. Zhao, Eugenia C. Greig, Darius M. Moshfeghi
D.M.M.– Ainsly Limited (E), Akebia (SAB), Alexion (C), Boehringer Ingelheim (C), Clinical Trials Resource Group (SAB), Clinical Trials Summit (H), dSentz Inc. (F, E, BOD), Feliqs Inc. (C), Icon (C, DSMB), InGel Therapeutics (DSMB), Insite DME (C), Ocular Therapeutix (C, E), Osanni Bio (C, E), Plenoptika Inc. (E), Pr3vent Inc. (F, E, BOD), Pykus (E), RetinaBio Inc. (E), Vanotech Chengdu (C), Vision Labs Ai Inc. (F, E), Promisight Inc. (E, disbanded), Grand Legend Technology Ltd. (E, defunct), Visunex (E, defunct), research to prevent blindness Inc. (G), NEI P30-EY026877 (G). Data sharing not applicable to this article as no datasets were generated or analysed during the current study.